Princeton, New Jersey, July 28, 2015– Sandoz today announced the US market introduction of its budesonide inhalation suspension, a generic version of Pulmicort Respules® (budesonide) inhalation suspension 1 mg strength by AstraZeneca LP.Sandoz’s budeso…
Non-communicable diseases like asthma are rising rapidly in sub-Saharan Africa where healthcare systems are ill-prepared to cope1 – Zambia is ranked #1 in the world for mortality due to asthma2Increasing the medical expertise of local healthcare profes…
Holzkirchen, Germany, July 22, 2015 – The US Court of Appeals for the Federal Circuit issued a ruling on July 21 that paves the way for Sandoz to launch Zarxio (filgrastim) after September 2, as the first US biosimilar.The court, which ruled following …
Basel, July 21, 2015 – Commenting on the results, Joseph Jimenez, CEO of Novartis, said: “Novartis had a strong quarter for innovation, with US approval and launch of both Entresto and Glatopa being key highlights. Additionally, we reported a broad ran…
The Balans programme focuses on educating patients about the benefits of probiotics, which help our digestive tract to metabolize the food we consume, maintain the health of our intestines, and support the function of our immune system.The use of probi…
Sandoz is proud to be a part of the Novartis Declaration for Patients, which Novartis introduced today at the Innovating for Patients event in Basel, Switzerland. The patient declaration is a public commitment to patients around the world of what they …
Tokyo, June 25, 2015 – Sandoz has announced the Japanese market introduction of three new products including clopidogrel, tacrolimus and pitavastatin (line extension).Clopidogrel, a generic version of Sanofi’s Plavix®, is used for suppression of recurr…
June 24, 2015 – Novartis has a strong history of CR activities, and transparent reporting is a central part of our commitment to corporate responsibility. We have publicly reported on our performance in this area since 2000 through our Annual Report an…
June 24, 2015 – Novartis has a strong history of CR activities, and transparent reporting is a central part of our commitment to corporate responsibility. We have publicly reported on our performance in this area since 2000 through our Annual Report an…
Glatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosisSandoz has begun shipping to US customers following recent FDA approvalNovartis and Sandoz are driving access to a …